1871. Rapid Adverse Event Following Immunization (AEFI) surveillance following a mass meningococcal B vaccine program in a university setting: a Canadian Immunization Research Network (CIRN) study
Session: Poster Abstract Session: Vaccines: Meningococcal
Saturday, October 10, 2015
Room: Poster Hall
Background:

On 15 Feb 2015 an institutional outbreak of Neisseria meningitidisserotype B (MenB) was declared at a small residential university in Nova Scotia following 2 cases (death on 01 Feb; meningococcemia on 11 Feb); public health initiated a mass vaccination program 15 Feb.

Methods:

The purpose of this study was to detect clinically significant AEFI (defined as a health care visit (HCV) in the 8 days post-vaccine) during a 2-dose 4 Component MenB vaccine (Bexero,™ Novartis Vaccines)campaign given in a 0, 1 month schedule. Public health clinics were held 18 Feb-21 Apr. Day 8 after the last set of clinics for each vaccine dose, all students received an email invitation to complete an online survey. Non-recipients of vaccine were invited to complete a control survey to detect HCV for any reason. The survey used the methods of the CIRN Canadian National Vaccine Safety Network (CANVAS) (http://cirnetwork.ca/network/national-ambulatory-network/method).

Results: Vaccine uptake was 84.8% for dose 1 (2967/3500) and 70% for dose 2 (2456/3500). Most vaccinees were 20-29 years of age (68.5%, 674/984 and 66.6%, 302/453, for doses 1 and 2 respectively). Among 984 vaccinees and 53 controls responding after dose 1, 40 had a HCV (3.9% vaccinees, 3.8% controls); 12 agreed to a phone interview. The most common complaint was “sore arm” and “systemically unwell”. Among 463 vaccinees and 10 controls post dose 2, 22 had a HCV (4.7% vaccinees). Onset of AEFI leading to HCVs occurred within 2-34 hours in most vaccinees (62% post dose 1 and 80% post dose 2).) No hospitalizations or severe AE were reported.

Conclusion:

A rapid AEFI surveillance program during an emergency MenB vaccination program was welcomed by public health and university administration, did not identify safety signals, and provided reassurance to the community.

 

Joanne Langley, MD, FSHEA1, Donna Macdougall, BScN, RN, PhD2, Beth Halperin, BScN, RN, MSc3, Ann Swain, MD4, Julie a. Bettinger, PhD5, Scott Halperin, MD6, Shelly a Mcneil, MD, FRCPC, FIDSA7, Gaston De Serres, MD8, Eve Dube, PhD8, Karina Top, MD, MS9, Donna Mackinnon-Cameron, MSc10 and Kim Marty, BSc11, (1)Pediatrics, Dalhousie University, Halifax, NS, Canada, (2)Nursing, Saint Frances Xavier University, Antigonish, NS, Canada, (3)Nursing, Dalhousie University, Halifax, NS, Canada, (4)Student Health, Acadia University, Wolfville, NS, Canada, (5)Pediatrics, Vaccine Evaluation Center, University British Columbia, Vancouver, BC, Canada, (6)Canadian Center for Vaccinology, IWK Health Centre and Capital Health, Dalhousie University, Halifax, NS, Canada, (7)Canadian Center for Vaccinology, IWK Health Center and Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada, (8)Institut National de Sante Publique, Quebec City, QC, Canada, (9)Canadian Centre for Vaccinology, IWK Health Centre, Halifax, NS, Canada, (10)Canadian Center for Vaccinology, Halifax, NS, Canada, (11)Child and Family Research Institute, Vancouver, BC, Canada

Disclosures:

J. Langley, None

D. Macdougall, None

B. Halperin, None

A. Swain, None

J. A. Bettinger, None

S. Halperin, None

S. A. Mcneil, None

G. De Serres, None

E. Dube, None

K. Top, None

D. Mackinnon-Cameron, None

K. Marty, None

Previous Abstract | Next Abstract >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.